Scarica l'app Stockscreener
762.00
0.69%
5.19
Dopo l'orario di chiusura:
762.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$756.81
Aprire:
$751.97
Volume 24 ore:
837.20K
Relative Volume:
1.30
Capitalizzazione di mercato:
$83.27B
Reddito:
$13.85B
Utile/perdita netta:
$4.65B
Rapporto P/E:
21.73
EPS:
35.06
Flusso di cassa netto:
$3.32B
1 W Prestazione:
-7.71%
1M Prestazione:
-23.08%
6M Prestazione:
-22.43%
1 anno Prestazione:
-5.04%
Intervallo 1D:
$750.20
$762.70
Intervallo di 1 settimana:
$750.20
$831.00
Portata 52W:
$750.20
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria - Nasdaq
Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP - Law360
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Benzinga
Braun Stacey Associates Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Geographical - openPR
2 Top Growth Stocks to Buy on the Dip - AOL
Swiss National Bank Has $338.08 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Seizert Capital Partners LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewswire Inc.
Mizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by CIBC Asset Management Inc - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research - MarketBeat
Citigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral Recommendation - MSN
Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria - Pharmaceutical Technology
Simplify Asset Management Inc. Purchases 3,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Check Out What Whales Are Doing With REGN - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research - MarketBeat
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S. - Seeking Alpha
ING Groep NV Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA to review Sanofi, Regeneron’s Dupixent sBLA for CSU - Pharmaceutical Business Review
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup - MarketBeat
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU - MarketWatch
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous - The Bakersfield Californian
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron stock touches 52-week low at $785.31 By Investing.com - Investing.com Nigeria
Regeneron stock touches 52-week low at $785.31 - Investing.com
Citigroup Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
28 Analysts Have This To Say About Regeneron Pharmaceuticals - Benzinga
Victory Capital Management Inc. Sells 2,273 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Los Angeles Capital Management LLC Sells 773 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citi initiated coverage on Regeneron Pharmaceuticals setting a price target of $895 - Investing.com
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals' SWOT analysis: stock faces biosimilar challenge, pipeline promise - Investing.com
Parametrica Management Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease - Yahoo Finance
MQS Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dillon & Associates Inc. Buys 878 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - The Manila Times
Aigen Investment Management LP Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to Unveil Breakthrough Blood Cancer Data: 23 Studies at ASH 2024 | REGN Stock News - StockTitan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight - PR Newswire
Bronte Capital Management Pty Ltd. Has $144.06 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $316.96 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Baker Avenue Asset Management LP Invests $707,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Familial Lipoprotein Lipase Deficiency Market Research - openPR
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.28%
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):